- Home
- TSHA vs CERT Comparison
TSHA vs CERT Comparison
Compare TSHA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | CERT |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TSHA | CERT |
|---|---|---|
| Price | $4.52 | $6.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $10.56 | ★ $12.22 |
| AVG Volume (30 Days) | 2.1M | ★ 3.0M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.50 | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | $8,333,000.00 | ★ $418,838,000.00 |
| Revenue This Year | N/A | $5.05 |
| Revenue Next Year | N/A | $5.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $1.13 | $6.04 |
| 52 Week High | $6.02 | $15.38 |
Technical Indicators
Market Signals| Indicator | TSHA | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 34.35 |
| Support Level | $4.41 | $6.04 |
| Resistance Level | $5.16 | $11.53 |
| Average True Range (ATR) | 0.20 | 0.39 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 20.13 | 40.20 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.